Nicole Mikula
Psychiatric/Mental Health · Binghamton, NYNPI 1598223174
Payments from drug & device makers
Across 196 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Neurocrine Biosciences, Inc.$738
- Teva Pharmaceuticals USA, Inc.$609
- Alkermes, Inc.$392
- Braeburn Inc.$246
- Johnson & Johnson$204
- plus $661 from 7 others
What the payments were for
- Food & beverage$4,32998%
- Education$1042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,583 |
| Neurocrine Biosciences, Inc. | 62 | $738 |
| Teva Pharmaceuticals USA, Inc. | 24 | $609 |
| Alkermes, Inc. | 14 | $392 |
| Braeburn Inc. | 2 | $246 |
| Johnson & Johnson | 7 | $204 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $162 |
| Otsuka America Pharmaceutical, Inc. | 6 | $153 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Corium, LLC | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,433 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $131,022 |
| VraylarCariprazine Hcl | 24 | $34,655 |
| Lurasidone Hcl | 11 | $13,227 |
| VyvanseLisdexamfetamine Dimesylate | 29 | $8,533 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $3,058 |
| Risperidone OdtRisperidone | 21 | $2,153 |
| Quetiapine Fumarate | 82 | $1,969 |
| Fluoxetine Hcl | 31 | $1,887 |
| Duloxetine Hcl | 77 | $1,051 |
| Hydroxyzine Hcl | 21 | $633 |
| Buspirone Hcl | 39 | $623 |
| Prazosin Hcl | 52 | $578 |
| Mirtazapine | 53 | $446 |
| Bupropion XlBupropion Hcl | 60 | $423 |
| Risperidone | 52 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $738 | $131,02217 claims |
| AbbVieVraylar | $1,583 | $34,65524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Binghamton
- Elijah StevensBinghamton$131K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Kayanna JonasFar Rockaway$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.